Shamburg News · 8-K filed Oct 27, 2026, 5:16 PM EDT
Spero Therapeutics COO Timothy Keutzer to Retire Effective December 31, 2026
SPRO · Spero Therapeutics, Inc.
- Leadership change
- Materiality: medium
On October 26, 2026, Spero Therapeutics, Inc. announced that Chief Operating Officer Timothy Keutzer will retire effective December 31, 2026. The Company expects to enter into a consulting arrangement with Mr. Keutzer on or about that date, providing transition advisory services until approximately February 28, 2027, at an hourly rate.
Source: SEC EDGAR, Form 8-K, Item 5.02, accession 0001193125-26-434452.
Written from the filing by Shamburg Markets. Figures are as reported by the company.